NIH study assessing COVID-19 vaccine in pregnant, postpartum moms
The National Institutes of Health launched a new observational study to evaluate the immune responses generated by COVID-19 vaccines in pregnant postpartum individuals. The study, dubbed MOMI-VAX, will also assess vaccine safety the transfer of vaccine-induced antibodies through breast milk.
“Tens of thousands of pregnant breastfeeding people in the United States have chosen to receive the COVID-19 vaccines available under emergency use authorization,” Dr. Anthony Fauci, director of National Institute of Allergy Infectious Diseases (NIAD), which is funding the study, said in a news release. “However, we lack robust, prospective clinical data on vaccination in these populations. The results of this study will fill gaps in our knowledge help inform policy recommendations personal decision-making on COVID-19 vaccination during pregnancy in the postpartum period.”
The study will enroll up to 750 pregnant people 250 postpartum individuals who are within two months of delivery have received or will receive a COVID-19 vaccine. The infants will also be enrolled in the study. Researchers will follow the pairs through the first year after delivery analyze blood samples regularly collected to assess development durability of vaccine-induced antibodies.
NOT ENOUGH DATA TO RECOMMEND COVID-19 BOOSTER VACCINES YET: CDC PANEL
Mothers will also have the option of submitting breast milk samples at two weeks, two months, six months 12 months after delivery to evaluate breast milk antibodies.
Prior studies have found evidence of antibody transfer through the placenta following vaccination, as well as through breast milk, but work is ongoing. Data recently released by the Centers for Disease Control Prevention (CDC) found pregnant women are getting vaccinated at lower rates than nonpregnant people, particularly younger populations. Of 136,000 pregnant women identified in the data, just 11.1% had completed vaccination.
CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE
Pregnant people are at an increased risk for severe illness from COVID-19 when compared to nonpregnant people, at increased risk for preterm birth or other poor pregnancy outcomes. When the COVID-19 vaccines received emergency use authorization from the FDA, the panel noted that not enough data was included in clinical trials on pregnant women. Currently, the CDC advises that pregnant people can receive a COVID-19 vaccine.